MDC is a high-tech innovative enterprise focusing on the research, development, production and sales of ophthalmic medical devices, and has a senior research and development team at home and abroad. At present, the company's best-selling product at home and abroad is Eyesis, the fourth generation of intense pulsed light (IPL) dry eye therapeutic instrument. This equipment adopts the multiple optimal pulse technology (MOPT), which has the international leading level and exclusive independent intellectual property rights in the industry. It can precisely modulate and control the controlled emission of intense pulsed light, so that the energy can reach the treatment site more accurately. So far, it has been applied and verified as a safe and effective innovative technology by hundreds of eye hospitals. In addition, the company has carried out a number of product research and development in the field of children's strabismus and amblyopia treatment, such as: electronic LCD amblyopia covering glasses and VR intelligent children's vision training system.